Doctors in Washington State gave remdesivir (Gilead antiviral drug) to the first coronavirus patient in the United States last week after his condition worsened and pneumonia developed when he’d been in the hospital for a week. His symptoms improved the next day.
Two clinical trials will take place in Wuhan, China, the center of the outbreak; 500 patients will receive the drug, and comparison groups will get a placebo. The patients will get the drug intravenously for 10 days, and then assessed 28 days after the treatment to see how they fared compared to the placebo groups
The New England Journal of Medicine -First Case of 2019 Novel Coronavirus in the United States
Remdesivir and chloroquine (anti-malarial) stops coronavirus in the lab.
Nature – Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
China has begun clinical trials of remdesivir.
There are currently limited available clinical supplies of remdesivir, but Gilead is working to increase the available supply as rapidly as possible. They had stockpiled the drug in case of an Ebola outbreak.
Wang is a prolific business-oriented writer of emerging and disruptive technologies. He is known for insightful articles that combine business and technical analysis that catches the attention of the general public and is also useful for those in the industries. He is the sole author and writer of nextbigfuture.com
, the top online science blog. He is also involved in angel investing and raising funds for breakthrough technology startup companies.
He gave the recent keynote presentation at Monte Jade event with a talk entitled the Future for You. He gave an annual update on molecular nanotechnology at Singularity University on nanotechnology, gave a TEDX talk on energy, and advises USC ASTE 527 (advanced space projects program). He has been interviewed for radio, professional organizations. podcasts and corporate events. He was recently interviewed by the radio program Steel on Steel on satellites and high altitude balloons that will track all movement in many parts of the USA.
He fundraises for various high impact technology companies and has worked in computer technology, insurance, healthcare and with corporate finance.
He has substantial familiarity with a broad range of breakthrough technologies like age reversal and antiaging, quantum computers, artificial intelligence, ocean tech, agtech, nuclear fission, advanced nuclear fission, space propulsion, satellites, imaging, molecular nanotechnology, biotechnology, medicine, blockchain, crypto and many other areas.